News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

April

12

electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance

Record revenue from product sales will be approximately $1.9M; approximately 60% growth over first quarter 2021...

14

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua

These rare forms of trigeminal autonomic cephalalgias are typically debilitating and difficult to treat...

Recent developments

April

12

electroCore Provides Business Update and Select First Quarter 2022 Financial Guidance

September

14

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua